Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States–dabigatran (Pradaxa®) and rivaroxaban (Xarelto®).
Investigators at the University of Minnesota are developing a research project aimed at providing afib patients with a better understanding of the effectiveness of the new oral anticoagulants in preventing strokes when compared to warfarin.
These researchers are seeking input as to what is most important to patients in the US. If you have Afib, please help us to shape this project by answering five brief questions and providing a few pieces of demographic data.
Take the survey at: Survey on Anticoagulant Use in Afib Patients